% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bochtler:126161,
      author       = {T. Bochtler$^*$ and U. Hegenbart and C. Kunz$^*$ and M.
                      Granzow and A. Benner$^*$ and A. Seckinger and C. Kimmich
                      and H. Goldschmidt and A. D. Ho and D. Hose and A. Jauch and
                      S. O. Schönland},
      title        = {{T}ranslocation t(11;14) is associated with adverse outcome
                      in patients with newly diagnosed {AL} amyloidosis when
                      treated with bortezomib-based regimens.},
      journal      = {Journal of clinical oncology},
      volume       = {33},
      number       = {12},
      issn         = {1527-7755},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2017-02276},
      pages        = {1371 - 1378},
      year         = {2015},
      abstract     = {Bortezomib has become a cornerstone in the treatment of AL
                      amyloidosis. In this study, we addressed the prognostic
                      impact of cytogenetic aberrations for bortezomib-treated
                      patients.We analyzed a consecutive series of 101 patients
                      with AL amyloidosis treated with bortezomib-dexamethasone as
                      first-line treatment by interphase fluorescence in situ
                      hybridization (iFISH). Patients were ineligible for
                      high-dose chemotherapy, which would put them at risk for
                      cardiac or renal failure, and thus represented a poor-risk
                      group.Presence of t(11;14), versus its absence, was
                      associated with inferior hematologic event-free survival
                      (median, 3.4 v 8.8 months, respectively; P = .002), overall
                      survival (median, 8.7 v 40.7 months, respectively; P = .05),
                      and remission rate (≥ very good partial remission; $23\%$
                      v $47\%,$ respectively; P = .02). In multivariable Cox
                      regression models incorporating established hematologic and
                      clinical risk factors, t(11;14) was an independent adverse
                      prognostic marker for hematologic event-free survival
                      (hazard ratio, 2.94; $95\%$ CI, 1.37 to 6.25; P = .006) and
                      overall survival (hazard ratio, 3.13; $95\%$ CI, 1.16 to
                      8.33; P = .03), but not for remission (≥ very good partial
                      remission). Markedly, the multiple myeloma high-risk iFISH
                      aberrations t(4;14), t(14;16), del(17p), and gain of 1q21
                      conferred no adverse prognosis in this
                      bortezomib-dexamethasone-treated group. After backward
                      variable selection, the final multivariable model was
                      validated in a consecutive series of 32 patients treated
                      with bortezomib, dexamethasone, and cyclophosphamide.iFISH
                      results are important independent prognostic factors in AL
                      amyloidosis. In contrast to our recently published results
                      with melphalan and dexamethasone standard therapy,
                      bortezomib is less beneficial to patients harboring
                      t(11;14), whereas it effectively alleviates the poor
                      prognosis inherent to high-risk aberrations. Given the
                      discrepant response to different treatment modalities, iFISH
                      may help to guide therapeutic choices in these poor-risk
                      patients requiring rapid hematologic response.},
      keywords     = {Boronic Acids (NLM Chemicals) / Immunoglobulin Light Chains
                      (NLM Chemicals) / Pyrazines (NLM Chemicals) / Bortezomib
                      (NLM Chemicals) / Dexamethasone (NLM Chemicals) /
                      Cyclophosphamide (NLM Chemicals)},
      cin          = {G330 / C060},
      ddc          = {050},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25779559},
      doi          = {10.1200/JCO.2014.57.4947},
      url          = {https://inrepo02.dkfz.de/record/126161},
}